2012
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery
Nguyen D, Mahon K, Chikh G, Kim P, Chung H, Vicari A, Love K, Goldberg M, Chen S, Krieg A, Chen J, Langer R, Anderson D. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: e797-e803. PMID: 22421433, PMCID: PMC3325698, DOI: 10.1073/pnas.1121423109.Peer-Reviewed Original ResearchConceptsToll-like receptorsSuppress influenza virus replicationVaccine adjuvantsActivation of Toll-like receptorsPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsInfluenza virus replicationType I IFN activityBlood mononuclear cellsResponses in vitroAdaptive immune responsesCell-mediated responsesTLR-expressing cellsIn vivo therapyCell-specific deliveryToll-like receptor 8Adjuvant deliveryAntiviral immunotherapySystemic biodistributionImidazoquinoline familyTLR7-dependentTLR7/8 agonistMononuclear cellsSubcutaneous injectionImmune response
2009
Inflammasome-activating biodegradable nanoparticulates as vaccine delivery systems (135.80)
Fahmy T, DEMENTO S, Eisenbarth S, Caplan M, Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell R. Inflammasome-activating biodegradable nanoparticulates as vaccine delivery systems (135.80). The Journal Of Immunology 2009, 182: 135.80-135.80. DOI: 10.4049/jimmunol.182.supp.135.80.Peer-Reviewed Original ResearchToll-like receptorsIL-1βInflammasome activationProinflammatory cytokines IL-1βAntigen-presenting cellsClass of nanomaterialsCytokines IL-1βSurface of nanoparticlesWest Nile encephalitisInnate immune pathwaysVaccine delivery systemWild-type macrophagesCellular immunityVaccination approachesMurine modelInflammasome activityType macrophagesImmune pathwaysAdjuvant deliveryDanger signalsVaccine designModel antigenLipopolysaccharideAntigenBiocompatible polyester
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply